Compare AbbVie Inc (ABBV) vs Futu Holdings Ltd (FUTU) Price & Performance

AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.

Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.

Futu Holdings Limited (FUTU) trades at $105.31, down 3.12% on the day. The stock shows strong fundamentals with a P/E of 11.63 and robust profitability, including a net income margin of 41.83% and ROE of 28.09%. Revenue grew to $22.85B in 2025, and cash flow from operations surged to $31.0B in 2024. Technical indicators are bullish, with moving averages supporting an uptrend and key support at $103. However, recent earnings misses and a securities class action lawsuit pose significant headwinds.

The outlook for FUTU is mixed; strong financial health and analyst consensus leaning buy (58.34%) suggest potential upside, but legal risks and earnings volatility require caution. Investors should weigh solid fundamentals against regulatory and litigation overhangs that could impact near-term performance.